GT
CYTK icon

Glenmede Trust’s Cytokinetics CYTK Stock Holding History

Glenmede Trust’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$613K Buy
7,191
+528
+8% +$37.9K ﹤0.01% 916
2026
Q1 		$439K Sell
6,663
-6,107
-48% -$388K ﹤0.01% 1011
2025
Q4 		$811K Buy
+12,770
New +$794K ﹤0.01% 781
2024
Q4 		– Sell
-6,261
Closed -$331K – 1399
2024
Q3 		$331K Sell
6,261
-2,761
-31% -$154K ﹤0.01% 1066
2024
Q2 		$489K Buy
9,022
+994
+12% +$60K ﹤0.01% 914
2024
Q1 		$563K Buy
8,028
+4,210
+110% +$326K ﹤0.01% 892
2023
Q4 		$319K Sell
3,818
-6,264
-62% -$227K ﹤0.01% 1018
2023
Q3 		$297K Sell
10,082
-2,161
-18% -$72K ﹤0.01% 992
2023
Q2 		$431K Hold
12,243
– – ﹤0.01% 871
2023
Q1 		$431K Sell
12,243
-823
-6% -$33.6K ﹤0.01% 876
2022
Q4 		$599K Sell
13,066
-247
-2% -$10.6K ﹤0.01% 793
2022
Q3 		$645K Sell
13,313
-5,611
-30% -$270K ﹤0.01% 755
2022
Q2 		$743K Buy
18,924
+6,654
+54% +$268K ﹤0.01% 750
2022
Q1 		$451K Buy
12,270
+164
+1% +$5.83K ﹤0.01% 926
2021
Q4 		$551K Buy
12,106
+459
+4% +$17.7K ﹤0.01% 898
2021
Q3 		$416K Buy
+11,647
New +$343K ﹤0.01% 946
2020
Q4 		– Sell
-982
Closed -$21K – 1476
2020
Q3 		$21K Buy
982
+73
+8% +$1.71K ﹤0.01% 1598
2020
Q2 		$21K Buy
909
+474
+109% +$8.89K ﹤0.01% 1567
2020
Q1 		$4K Hold
435
– – ﹤0.01% 2710
2019
Q4 		$4K Sell
435
-173
-28% -$1.78K ﹤0.01% 2710
2019
Q3 		$6K Buy
608
+107
+21% +$1.34K ﹤0.01% 2557
2019
Q2 		$5K Buy
501
+215
+75% +$2.07K ﹤0.01% 2617
2019
Q1 		$2K Buy
286
+62
+28% +$456 ﹤0.01% 2821
2018
Q4 		$1K Buy
+224
New +$1.64K ﹤0.01% 2873
2016
Q4 		– Sell
-88
Closed – – 2497
2016
Q3 		$0 Buy
+88
New +$919 ﹤0.01% 2600
2013
Q4 		– Sell
-17,905
Closed -$138K – 2285
2013
Q3 		$138K Buy
+17,905
New +$192K ﹤0.01% 1265

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Glenmede Trust's CYTK Position: Q2 2026 in Review

Glenmede Trust increased its Cytokinetics (CYTK) stake by 7.9% in Q2 2026, buying an estimated $37.9K and bringing the position to 7,191 shares worth $613K. The position accounts for ﹤0.01% of the portfolio, ranked #916.

Glenmede Trust first reported a position in CYTK in Q3 2013 and has held it in 26 quarters since. The position peaked at $811K in Q4 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Glenmede Trust held 7,191 shares of Cytokinetics worth $613K as of Q2 2026.
  • Glenmede Trust bought 528 Cytokinetics shares in Q2 2026, an estimated $37.9K.
  • Cytokinetics made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #916 holding.
  • Glenmede Trust first reported a position in Cytokinetics in Q3 2013 and has held it in 26 quarters since.
  • Glenmede Trust's Cytokinetics position peaked at $811K in Q4 2025.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.